You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR OPTIMARK


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OPTIMARK

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00530101 ↗ The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity Completed Mallinckrodt Phase 1 2004-07-01 The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
NCT00530101 ↗ The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity Completed University of Miami Phase 1 2004-07-01 The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
NCT00862459 ↗ Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Completed Bayer Phase 2 2005-08-01 The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI with Gadavist Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with OptiMARK.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OPTIMARK

Condition Name

Condition Name for OPTIMARK
Intervention Trials
Brain Diseases 1
Breast Cancer 1
Pathological Processes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OPTIMARK
Intervention Trials
Pathologic Processes 1
Spinal Cord Diseases 1
Brain Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OPTIMARK

Trials by Country

Trials by Country for OPTIMARK
Location Trials
United States 28
Colombia 3
Argentina 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OPTIMARK
Location Trials
Florida 3
Pennsylvania 2
Missouri 2
California 2
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OPTIMARK

Clinical Trial Phase

Clinical Trial Phase for OPTIMARK
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OPTIMARK
Clinical Trial Phase Trials
Completed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OPTIMARK

Sponsor Name

Sponsor Name for OPTIMARK
Sponsor Trials
Mallinckrodt 2
University of Miami 1
Bayer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OPTIMARK
Sponsor Trials
Industry 4
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.